$61.29
0.51% yesterday
NYSE, Nov 25, 10:00 pm CET
ISIN
US1488061029
Symbol
CTLT
Sector
Industry

Catalent Inc Stock price

$61.29
+2.20 3.72% 1M
+6.47 11.80% 6M
+16.36 36.41% YTD
+22.18 56.71% 1Y
-68.30 52.70% 3Y
+8.44 15.97% 5Y
+33.44 120.07% 10Y
NYSE, Closing price Mon, Nov 25 2024
+0.31 0.51%
ISIN
US1488061029
Symbol
CTLT
Sector
Industry

Key metrics

Market capitalization $11.12b
Enterprise Value $15.74b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 158.96
EV/Sales (TTM) EV/Sales 3.56
P/S ratio (TTM) P/S ratio 2.52
P/B ratio (TTM) P/B ratio 3.14
Revenue growth (TTM) Revenue growth 4.39%
Revenue (TTM) Revenue $4.42b
EBIT (operating result TTM) EBIT $155.00m
Free Cash Flow (TTM) Free Cash Flow $99.00m
Cash position $335.00m
EPS (TTM) EPS $-2.27
P/E forward negative
P/S forward 2.40
EV/Sales forward 3.40
Short interest 5.25%
Show more

Is Catalent Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Catalent Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Catalent Inc forecast:

10x Hold
91%
1x Sell
9%

Analyst Opinions

11 Analysts have issued a Catalent Inc forecast:

Hold
91%
Sell
9%

Financial data from Catalent Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4,422 4,422
4% 4%
100%
- Direct Costs 3,457 3,457
6% 6%
78%
965 965
1% 1%
22%
- Selling and Administrative Expenses 303 303
8% 8%
7%
- Research and Development Expense 17 17
0% 0%
0%
645 645
4% 4%
15%
- Depreciation and Amortization 490 490
13% 13%
11%
EBIT (Operating Income) EBIT 155 155
18% 18%
4%
Net Profit -413 -413
58% 58%
-9%

In millions USD.

Don't miss a Thing! We will send you all news about Catalent Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Catalent Inc Stock News

Positive
Reuters
4 days ago
EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent , a person with direct knowledge of the matter said on Friday.
Neutral
Reuters
13 days ago
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the matter said.
Negative
Reuters
21 days ago
Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.
More Catalent Inc News

Company Profile

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulate, develop, and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufacture services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies, and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.

Head office United States
CEO Alessandro Maselli
Employees 16,900
Founded 1933
Website www.catalent.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today